Neurogenesis Impairment in 4R-Tauopathies

Neurogenesis Impairment in 4R-Tauopathies

Overview

4R-tauopathies represent a family of neurodegenerative disorders characterized by the predominant accumulation of 4-repeat (4R) tau isoforms in neuronal and glial inclusions. The five primary 4R-tauopathies — [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-syndrome) (CBD), [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease) (AGD), [Globular Glial Tauopathy](/diseases/ggt) (GGT), and [Frontotemporal Dementia with Parkinsonism linked to Chromosome 17](/diseases/ftdp-17) (FTDP-17) — all share a common pathological thread: tau pathology that directly or indirectly disrupts the brain's capacity for adult neurogenesis. [@bhatt2023]

Adult neurogenesis occurs in two primary neurogenic niches: the subgranular zone (SGZ) of the hippocampal dentate gyrus and the subventricular zone (SVZ) lining the lateral ventricles. These niches contain neural stem cells (NSCs) that give rise to new neurons throughout life. In 4R-tauopathies, tau pathology impairs neurogenesis at multiple stages: NSC proliferation, neural progenitor cell (NPC) survival, migration, differentiation, and synaptic integration. The result is a progressive decline in the brain's endogenous regenerative capacity, which likely contributes to the cognitive, behavioral, and motor decline that characterizes these disorders. [@holmes2024]

Neurogenesis Impairment in 4R-Tauopathies

Overview

4R-tauopathies represent a family of neurodegenerative disorders characterized by the predominant accumulation of 4-repeat (4R) tau isoforms in neuronal and glial inclusions. The five primary 4R-tauopathies — [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-syndrome) (CBD), [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease) (AGD), [Globular Glial Tauopathy](/diseases/ggt) (GGT), and [Frontotemporal Dementia with Parkinsonism linked to Chromosome 17](/diseases/ftdp-17) (FTDP-17) — all share a common pathological thread: tau pathology that directly or indirectly disrupts the brain's capacity for adult neurogenesis. [@bhatt2023]

Adult neurogenesis occurs in two primary neurogenic niches: the subgranular zone (SGZ) of the hippocampal dentate gyrus and the subventricular zone (SVZ) lining the lateral ventricles. These niches contain neural stem cells (NSCs) that give rise to new neurons throughout life. In 4R-tauopathies, tau pathology impairs neurogenesis at multiple stages: NSC proliferation, neural progenitor cell (NPC) survival, migration, differentiation, and synaptic integration. The result is a progressive decline in the brain's endogenous regenerative capacity, which likely contributes to the cognitive, behavioral, and motor decline that characterizes these disorders. [@holmes2024]

This page provides a cross-disease comparison of how each 4R-tauopathy affects adult neurogenesis, identifies shared and distinct mechanisms, and highlights therapeutic implications.

Tau Isoform Biology and 4R Specificity

The tau protein is encoded by the [MAPT gene](/genes/mapt) on chromosome 17. Alternative splicing of MAPT pre-mRNA produces six tau isoforms in the adult human brain, distinguished by the presence of 3 or 4 microtubule-binding repeat domains (3R or 4R). Under normal conditions, the 3R:4R ratio is roughly balanced at approximately 1:1 in most brain regions. In 4R-tauopathies, pathological mutations or dysregulation cause a shift toward 4R tau dominance. [@bruno2023]

The 4R tau isoforms have several properties relevant to neurogenesis impairment:

• Increased microtubule binding affinity: 4R tau binds more tightly to microtubules, disrupting axonal transport and neuronal polarity that are essential for proper neurite outgrowth during neurogenesis
• Greater aggregation propensity: 4R tau is more prone to form insoluble fibrils, leading to the characteristic inclusions seen in PSP neurofibrillary tangles (NFTs), CBD astrocytic plaques, AGD grains, GGT globular inclusions, and FTDP-17 neuronal tangles
• Differential effects on NPC fate: Recent studies show that 4R tau specifically promotes astrogliogenesis over neurogenesis in neural progenitor populations, biasing differentiation away from new neuron generation [@bruno2023]

Cross-Disease Comparison

Progressive Supranuclear Palsy (PSP)

PSP is the most extensively studied 4R-tauopathy with respect to neurogenesis impairment. Neuropathological studies demonstrate significant NFT burden in the hippocampus, particularly in the CA1 and subiculum regions, which directly overlay the SGZ neurogenic niche. [@holmes2024]

Hippocampal neurogenesis in PSP:

• NPC proliferation is reduced by approximately 40% in PSP patients compared to age-matched controls
• The reduction is most pronounced in the posterior hippocampus, correlating with the distribution of NFTs
• Doublecortin (DCX)+ immature neurons are markedly reduced in PSP dentate gyrus
• BDNF expression is significantly decreased in PSP hippocampus, creating a trophic support deficit for new neuron survival [@ibanez2024]

• Tau pathology spreads transneuronally into the SVZ from affected periventricular structures
• Neuroblast migration via the rostral migratory stream (RMS) is impaired, contributing to olfactory dysfunction observed in PSP patients
• Astrogliosis in the SVZ creates a physical barrier to NPC proliferation

Corticobasal Degeneration (CBD)

CBD shows neurogenesis impairment through a distinct pattern: prominent involvement of the basal ganglia and cortical regions leads to widespread effects on both SVZ and SGZ niches. [@wan2023]

Hippocampal neurogenesis in CBD:

• NFT burden in the CBD hippocampus is less uniform than in PSP, with greater involvement of the entorhinal cortex and perforant path input zones
• This pattern disrupts the perforant path that carries sensory information into the dentate gyrus, reducing the functional activation needed to stimulate neurogenesis
• Synaptic dysfunction from cortical CBD pathology reduces activity-dependent neurogenic stimulation

• Direct tau pathology extends into the SVZ from striatal and pallidal foci
• Loss of striatal output disrupts the regulatory signaling that normally promotes SVZ neurogenesis
• Astroglial plaques characteristic of CBD form in periventricular white matter, physically disrupting the SVZ niche

Argyrophilic Grain Disease (AGD)

AGD is the most common 4R-tauopathy at autopsy, though often clinically underdiagnosed. AGD is characterized by argyrophilic grains — spindle-shaped tau inclusions — predominantly in limbic structures including the amygdala, hippocampus, and entorhinal cortex. [@martinez2022]

Hippocampal neurogenesis in AGD:

• The limbic predilection of AGD places the pathology directly within the hippocampal formation, the site of SGZ neurogenesis
• Grain pathology in the molecular layer of the dentate gyrus creates a physical barrier to dendrite development of newly generated granule cells
• AGD patients show significant impairment in pattern separation tasks — a dentate gyrus function that depends on adult-born neurons

• Grains accumulate in the septal nuclei and hypothalamus, disrupting neuroendocrine signaling that modulates neurogenesis
• AGD is frequently comorbid with AD pathology, and the combined amyloid-tau pathology has synergistic detrimental effects on neurogenesis
• The grain pathology affects the serotonergic raphe nuclei, reducing serotonergic input to the dentate gyrus, which is a key positive regulator of SGZ neurogenesis

Globular Glial Tauopathy (GGT)

GGT is the most recently defined 4R-tauopathy, characterized by globular tau inclusions in astrocytes and oligodendrocytes. GGT has been divided into three subtypes based on which glial cell type is predominantly affected: GGT type 1 (astrocyte predominant), type 2 (oligodendrocyte predominant), and type 3 (mixed). [@kelley2024]

Hippocampal neurogenesis in GGT:
GGT type 1 (astrocyte predominant) has the greatest impact on neurogenesis because astrocytes are critical components of the neurogenic niche:

• Reactive astrocytes in GGT adopt a harmful phenotype that actively suppresses NPC proliferation through D-serine and cytokine release
• The globular astrocytic inclusions impair astrocyte function in glutamate recycling, creating excitotoxic stress on NPCs
• Oligodendrocyte dysfunction in GGT type 2 disrupts myelination of hippocampal output pathways, impairing the activity-dependent signals that stimulate neurogenesis

• Astrocyte-predominant GGT (type 1) causes the most severe neurogenesis impairment because it directly disrupts the NSC niche cellular ecosystem
• Oligodendrocyte-predominant GGT (type 2) impairs oligodendrocyte precursor cell (OPC) differentiation alongside NPC dysfunction, affecting both neuro- and gliogenesis
• Mixed GGT (type 3) shows intermediate effects, with both neuronal and glial pathways contributing to neurogenesis decline

FTDP-17 (MAPT Mutations)

FTDP-17 is caused by autosomal dominant mutations in the [MAPT gene](/genes/mapt), making it a genetic model for understanding how tau dysfunction directly causes neurogenesis impairment. Several MAPT mutations (N279K, P301L, V337M, R406W) are associated with FTDP-17, each with somewhat different effects on neurogenesis. [@chen2025]

Direct tau mutation effects:

• MAPT mutations alter the 3R/4R splicing ratio, typically favoring 4R tau expression
• Mutant tau shows increased aggregation, forming the characteristic FTDP-17 NFTs
• The mutations affect tau's normal function in microtubule stabilization, impairing the cytoskeletal dynamics needed for new neuron process extension and synaptic integration

• Studies of FTDP-17 patient-derived iPSC neurons show that MAPT mutations directly impair neuronal differentiation from NPCs
• P301L and V337M mutations cause particularly severe NPC differentiation defects, with cells tending to adopt astrocyte fate instead
• R406W mutation carriers show a slower disease progression that correlates with less severe NPC differentiation impairment

• iPSC-derived NPCs from FTDP-17 patients allow direct investigation of how mutant tau disrupts neurogenic pathways
• CRISPR-based MAPT correction in patient-derived cells can rescue neurogenesis deficits, demonstrating therapeutic potential
• The genetic clarity of FTDP-17 helps isolate tau-specific effects from the secondary neuroinflammation and network dysfunction seen in sporadic 4R-tauopathies

Shared Mechanisms of Neurogenesis Impairment

Despite the clinical and pathological differences among the five 4R-tauopathies, they share several common mechanisms of neurogenesis impairment:

Tau-Mediated Direct Toxicity

Pathological 4R tau directly impairs NPCs through multiple mechanisms:

• Microtubule destabilization: Tau normally binds and stabilizes microtubules; in its pathological state, tau loses this function and can actually destabilize existing microtubules. NPCs are highly sensitive to microtubule dynamics for their cell division, migration, and process outgrowth.
• Oxidative stress: Tau pathology increases reactive oxygen species (ROS) production in NPCs, causing DNA damage and mitochondrial dysfunction. [@gatesandi2022]
• Calcium dysregulation: Pathological tau disrupts calcium homeostasis in NPCs, leading to premature differentiation and apoptosis.
• ER stress: Tau aggregation activates the unfolded protein response, which suppresses NPC proliferation.

Trophic Factor Deficiency

All 4R-tauopathies cause reductions in key neurotrophic factors:

• BDNF: Brain-derived neurotrophic factor levels are consistently reduced in 4R-tauopathy brains. BDNF is the most critical trophic factor for NPC survival, differentiation, and synaptic integration. [@ibanez2024]
• GDNF: Glial cell line-derived neurotrophic factor supports SVZ neurogenesis; its reduction in 4R-tauopathies impairs RMS migration.
• VEGF: Vascular endothelial growth factor promotes NPC proliferation; its downregulation in tauopathy reduces the vascular niche support for neurogenesis.

Neuroinflammation

Microglial activation is a universal feature of 4R-tauopathies. Activated microglia release cytokines that suppress neurogenesis:

• IL-1β: Interleukin-1β directly inhibits NPC proliferation and biases differentiation toward astrocyte fate
• TNF-α: Tumor necrosis factor-alpha induces NPC apoptosis and disrupts synaptic integration
• IL-6: Interleukin-6 suppresses NPC self-renewal and promotes inflammatory astrocyte transformation
• C1q: Complement component C1q marks newly born neurons for microglial phagocytosis, reducing their survival

Tau Spreading into Neurogenic Niches

Pathological tau propagates from affected neurons into the neurogenic niches through several mechanisms:

• Transneuronal spread: Tau seeds travel across synapses from affected neurons to NPCs and neuroblasts in the SVZ and SGZ
• CSF-mediated spread: Tau seeds in the CSF can access the ventricular system, exposing the SVZ directly
• Astrocyte-mediated transfer: Tau can move from affected astrocytes (especially in CBD and GGT) into adjacent NPCs

Network Dysfunction

Even NPCs that escape direct tau pathology are affected by the broader network dysfunction:

• Hippocampal circuits damaged by NFT burden provide insufficient activity-dependent signals to stimulate neurogenesis
• Loss of cholinergic input from the basal forebrain reduces a key positive regulator of dentate gyrus neurogenesis
• Reduced theta rhythm generation (from CA1 pathology) impairs the temporal encoding needed for new neuron integration

Comparative Summary

| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| Primary hippocampal involvement | CA1/subiculum | Entorhinal cortex | Dentate gyrus (limbic) | Variable by subtype | CA1, entorhinal |
| SGZ neurogenesis impairment severity | Severe | Moderate-severe | Moderate | Severe (type 1) | Moderate-severe |
| SVZ involvement | Moderate (secondary) | Prominent (striatal proximity) | Moderate (olfactory) | Moderate | Moderate |
| Primary NPC suppression mechanism | Tau NFTs in SGZ | Astrogliosis + network loss | Grain pathology in limbic | Astrocyte dysfunction | Direct tau mutation |
| BDNF reduction | Severe | Moderate | Moderate | Moderate-severe | Moderate |
| Microglial contribution | Moderate | Severe | Mild-moderate | Moderate | Mild |
| Olfactory dysfunction link | Yes | Yes | Yes | Less prominent | Variable |
| iPSC model availability | Limited | Yes | No | No | Yes |
| Key clinical correlate | Pseudobulbar palsy, falls | Alien limb, apraxia | Memory impairment | Gait, behavioral | Family history |

[@robinson2024]

Pathway Diagram

Therapeutic Implications

Targeting Neurogenesis in 4R-Tauopathies

The neurogenesis impairment seen across 4R-tauopathies suggests several therapeutic strategies: [@kim2025]

Tau-reducing approaches:

• Antisense oligonucleotides (ASOs) targeting MAPT mRNA to reduce total tau production
• Small molecule tau aggregation inhibitors to prevent the formation of toxic tau species
• Immunotherapies (active and passive) to clear pathological tau from neurogenic niches

• BDNF mimetics and TrkB agonists to restore trophic support for NPCs
• PDE5 inhibitors (sildenafil, tadalafil) to enhance cGMP signaling in NPCs
• Small molecules activating the Wnt/β-catenin pathway to directly stimulate NPC proliferation
• Exercise and environmental enrichment protocols for non-pharmacological neurogenesis enhancement

• Reduce toxic tau burden to remove the suppressor
• Simultaneously provide trophic support to restore NPC function
• This two-pronged strategy addresses both the cause and consequence of neurogenesis impairment

• iPSC-derived NPCs transplanted into the hippocampus could replace the endogenous NPC population lost to tauopathy
• Gene-corrected NPCs (for FTDP-17) could provide functional rescue
• Clinical trials of NPC transplantation for tauopathies are in early planning stages

Cross-Linking and Related Pages

Disease Pages

• [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration)
• [Argyrophilic Grain Disease (AGD)](/diseases/argyrophilic-grain-disease)
• [Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17)](/diseases/ftdp-17)
• [4R-Tauopathies Genetics](/diseases/4r-tauopathies-genetics)

Related Mechanisms

• [Adult Neurogenesis in Neurodegenerative Disease](/mechanisms/neurogenesis)
• [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Neuroinflammation and Neurogenesis Crosstalk](/mechanisms/neuroinflammation-neurogenesis)

Cell Type Pages

• [Hippocampal Neural Stem Cells](/cell-types/hippocampal-neural-stem-cells)
• [Subventricular Zone Neural Stem Cells](/cell-types/svz-neural-stem-cells)
• [Adult Neural Stem Cells](/cell-types/adult-neural-stem-cells)
• [Dentate Gyrus Stem Cells](/cell-types/dentate-gyrus-stem-cells)
• [Lateral Ventricle Neural Stem Cells](/cell-types/lateral-ventricle-neural-stem-cells)

Gene Pages

• [MAPT (Microtubule-Associated Protein Tau)](/genes/mapt)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Neurogenesis Impairment in 4R-Tauopathies discovered through SciDEX knowledge graph analysis: